ESTRO 2024 - Abstract Book

S2405

Clinical - Urology

ESTRO 2024

Keywords: PET,Prostate,Gallio

1162

Digital Poster

Younger age is an unfavorable predictor of outcomes in postoperative radiotherapy of prostate cancer

Silvia Paolinelli 1,2 , Letizia Cavallini 1,2 , Filippo Mammini 1,2 , Alessandra D'Alterio 1,2 , Erika Galietta 1,2 , Giorgio Coco 1,2 , Elena Natoli 1,2 , Viola Laghi 1,2 , Milly Buwenge 1 , Patrick Duhanxhiu 1 , Gabriella Macchia 3 , Francesco Deodato 3,4 , Annalisa Cortesi 5 , Selena Ciabatti 6 , Claudio Malizia 7 , Savino Cilla 8 , Michele Benedetti 9 , Antonio Malorgio 10 , Francesca Maurizi 11 , Ilaria Moschini 12 , Maria Ntreta 2 , Silvia Cammelli 1,2 , Alessio Giuseppe Morganti 1,2 , Alessandra Arcelli 2 1 Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, Bologna, Italy. 2 Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. 3 Radiation Oncology Unit, Gemelli Molise Hospital- Università Cattolica del Sacro Cuore, Campobasso, Italy. 4 Istituto di Radiologia, Università Cattolica del Sacro Cuore, Roma, Italy. 5 Radiotherapy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy. 6 Radiotherapy Department, Ospedale Bellaria, Bologna, Italy. 7 Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. 8 Medical Physics Unit, Gemelli Molise Hospital- Università Cattolica del Sacro Cuore, Campobasso, Italy. 9 Radiotherapy Department, “Infermi” Hospital, Rimini, Italy. 10 Department of Radiotherapy, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy. 11 Radiation Oncology, A.O. Ospedali Riuniti Marche Nord, Pesaro, Italy. 12 Radiotherapy Department, Azienda Ospedaliera di Piacenza, Piacenza, Italy

Purpose/Objective:

The aim of this study was to identify prognostic factors for optimizing postoperative radiotherapy (PORT) outcomes in patients with prostate cancer (PCa) at high risk of recurrence or detectable PSA following radical prostatectomy (RP).

Material/Methods:

We analyzed patient, tumor, and treatment-related data from a multicenter observational study, focusing on PCa patients who received PORT within one year after RP. Our study assessed biochemical relapse-free survival (bRFS), local control (LC), regional control (RC), metastasis-free survival (MFS), disease-free survival (DFS), and overall survival (OS). Univariate (logrank) and multivariate (Cox's) analyses were conducted, considering patient characteristics (age and Charlson's comorbidity index), tumor factors (pre- and post-RP PSA levels, ISUP grade, pT stage, and pN stage), and treatment details (e.g., prophylactic nodal irradiation [PNI], androgen deprivation therapy [ADT] type and duration, PORT fractionation and technique, image-guidance system, CTV to PTV margin, and EQD2 α/β=1.5 to the prostate bed and pelvic nodes). Parameters with p-values below 0.2 in univariate analysis were included in the multivariate analysis.